Pharmaceutical care recommendations for antiviral treatments in children with coronavirus disease 2019
- PMID: 32166483
- PMCID: PMC7090514
- DOI: 10.1007/s12519-020-00353-5
Pharmaceutical care recommendations for antiviral treatments in children with coronavirus disease 2019
Conflict of interest statement
Author declares no conflict of interests in the past 36 months.
Comment in
-
COVID-19 anticoagulation recommendations in children.Pediatr Blood Cancer. 2020 Sep;67(9):e28485. doi: 10.1002/pbc.28485. Epub 2020 Jun 18. Pediatr Blood Cancer. 2020. PMID: 32558124 Free PMC article. No abstract available.
References
-
- National Health Commission of the People's Republic of China. Notice on printing and distributing the diagnosis and treatment plan of COVID-19 (trial version 6). https://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8ae.... Accessed 19 Feb 2020.
-
- Shang XY, Huang Y, Liu EM, Chen Q, Cao L, Lu M, et al. A multicenter clinical study on the treatment for children's acute bronchiolitis by nebulized recombinant human interferon α1b. Chin J Pract Pediatr. 2014;29:840–844.
-
- Cui LD, Jin ZP, Wang Q, Cheng YB, Wang QS, PICU of Zhengzhou Children’s Hospital et al. The effect of recombinant human interferon α1b combined with human normal immunoglobulin on serum cytokine and immunoglobulins levels in bronchiolitis children. Chin J Hosp Pharm. 2018;38:403–406.
-
- Zhong QL, Zheng YW, Yan JJ, Deng YF, Tang L, Cui ZL, et al. The contrast observation of the clinical efficacy and safety of interferon nebulization and ribavirin in the treatment of infantile herpes angina. Chin Med Pharm. 2017;7:80–82.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources